Posters

Evolution of posterior capsule opacification and vision with TECNIS and Clareon intraocular-lens platforms

Poster Details

First Author: T.Martínez Rincón SPAIN

Co Author(s):    C. Almenara   D. Soriano   F. Bartol-Puyal   V. Polo   J. Larrosa   L. Pablo     

Abstract Details

Purpose:

To compare the progression of posterior capsule opacification (PCO) after implantation of two different intraocular-lens (IOL) platforms: Tecnis (Johnson&Johnson) and Clareon (Alcon).

Setting:

Miguel Servet University Hospital, Zaragoza, Spain.

Methods:

Observational study including 49 eyes (49 patients) with Tecnis ZCB00 IOL (group 1) and 65 eyes (65 patients) with Clareon IOL (group 2), with an axial length (AL) between 22 and 25 mm. Exclusion criteria were: amblyopia, ocular pathologies and previous intraocular treatment/surgery. The test performed one and six months after cataract surgery were: mesopic visual acuity (VA), CSV-1000E test, OQAS (optical quality analysis system), Catquest-9SF questionnaire and posterior capsule opacification (PCO) using slit-lamp pictures. The OQAS includes: modulation transfer function cut-off, objective scatter index, Strehl ratio, and VA with 100, 20 and 9% of contrast sensitivity (CS).

Results:

Mean age was 72.78±6.49 years old (p=0.63). Within group 1, there were no differences in mesopic VA (p=0.32), CSV-1000E (p>0.05), OQAS (p>0.05) and nearly all the questionnaire (p>0.05). There were in VA with 9% CS (p=0.03), item 2 (p=0.04) and the total value (p=0.003) of the questionnaire, and PCO intensity (p=0.004). Within group 2, there were not in mesopic VA (p=0.27), CSV-1000E (p>0.05), OQAS (p>0.05), and nearly all the questionnaire items (p>0.05). There were in items 3 (p=0.03), 8 (p=0.02) and the total value (p<0.001) of the questionnaire, and PCO intensity (p=0.01).

Conclusions:

Minor differences regarding vision occur in patients implanted with these IOL up to the sixth month after surgery. With both platforms (Tecnis ZCB00 and Clareon) patients may experience a reduction in their VA with very low contrast due to PCO, despite reporting an increase in their quality of life.

Financial Disclosure:

... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a competing company